Compare International Business Machines Corp (IBM) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
International Business Machines Corp vs Merck & Co., Inc. — how do they compare? International Business Machines Corp trades at $225.71 (market cap $213.50B), while Merck & Co., Inc. trades at $142.17 (market cap $351.28B). The key difference: Merck & Co., Inc. is the larger of the two by market cap, and International Business Machines Corp pays the higher dividend (2.98%). Which is the better fit depends on your goals — on Pluang, investors hold International Business Machines Corp for 88 Days and Merck & Co., Inc. for 98 Days on average.
| IBM | MRK | |
|---|---|---|
Market Cap | $213.50B | $351.28B |
Volume | 8,908,687 | 7,969,665 |
Sector | Technology | Health |
52-Week High | $329.23 | $156.43 |
52-Week Low | $205.77 | $82.49 |
Typical Hold Time | 88 Days | 98 Days |
Enterprise Value | $270.64B | $398.04B |
Dividend Yield | 2.98% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBM trades at $220.51, down 0.35% with a bearish technical signal. The company reported strong Q1 2026 earnings beat but missed Q2 expectations. Revenue growth accelerated to $67.54B in 2025 with improved net margin of 15.52%. Recent news highlights IBM's AI platform expansion with self-hosted deployment options, while analyst consensus remains positive with a $256.69 price target representing 16% upside potential.
IBM presents a mixed investment case with solid fundamentals offset by technical weakness. The company's pivot to hybrid cloud and AI consulting shows promise with $5.5B in generative AI bookings, but faces execution risks amid cyclical mainframe weakness. Current valuation at 20.13 P/E appears reasonable given the 34.62% ROE, though near-term price pressure may persist until Q3 earnings clarity emerges.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About International Business Machines Corp
International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
